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Objective: Radiofrequency ablation applies thermal energy with a catheter delivery
system, resulting in coagulation necrosis. Radiofrequency ablation is frequently
used for hepatic malignant tumors, but few reports exist regarding its use for lung
tumors. We report our experience with radiofrequency ablation for the treatment of
pulmonary malignant tumors.
Methods: We evaluated the results of lung radiofrequency ablation for patients not
considered surgical candidates. Indications for radiofrequency ablation were pul-
monary malignant tumors in patients with medical comorbidities, pulmonary com-
promise, or refusal of surgery.
Results: Thirty-three lung tumors in 18 patients (12 male, 6 female) were treated
with radiofrequency ablation. Tumors included metastatic carcinoma (n  8),
sarcoma (n  5), and lung cancer (n  5). Mean age was 60 years (range 27-95
years). Thoracic surgeons performed radiofrequency ablation by minithoracotomy
(n  5) or computed tomography-guided percutaneous methods (n  13) with
patients under general anesthesia in the operating room. Mean length of stay was 3
days (range 1-7 days). Complications included procedure-related pneumothorax in
7 of 13 percutaneous procedures (53.8%), delayed pneumothorax (1/18), pneumo-
nitis/pneumonia (4/18), small pleural effusion (9/18) and transient renal failure
(1/18). One death occurred as a result of hemoptysis 19 days after radiofrequency
ablation of a central nodule. This patient had also received recent brachytherapy.
After a mean follow-up of 6 months (range 1-14 months), radiofrequency ablation
had achieved a radiographically determined response in 8 of 12 patients with treated
tumors smaller than 5 cm (66.6%). Death with progressive metastatic disease
occurred in 7 of 18 patients (38%) during follow-up.
Conclusion: This pilot study demonstrates the feasibility of radiofrequency ablation
for small peripheral lung tumors. Larger tumors responded poorly. Additional trials
are needed to determine safety and efficacy.
Lung cancer is currently the most common cause of cancer-relateddeath in the United States and represents the second most commonmalignancy, with 171,400 new cases in the year 1999.1,2 Surgicalresection remains the mainstay of therapy for early stage non–smallcell lung cancer (NSCLC) and is also beneficial for selected patientswith limited pulmonary metastases from extrathoracic primary tu-
mors.3
There are patients with malignant pulmonary disease who would potentially
benefit from surgical therapy, however, but face a prohibitive surgical risk because
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of poor pulmonary function or severe medical comorbidi-
ties. Treatment alternatives to surgery include chemother-
apy and radiation, and in general long-term survivals are
lower than those achieved with complete resection. As an
alternative, these patients could potentially benefit from
minimally invasive ablative therapies that preserve unaf-
fected lung parenchyma. Radiofrequency ablation (RFA)
has been used extensively in the treatment of liver tumors in
patients who are not candidates for resection.4,5 RFA is a
thermal energy delivery system that applies an alternating
current supplied by a radiofrequency energy generator de-
livered though a needle electrode. After introduction of the
needle electrode into the tissue, multiple tines or hooks are
deployed within the tumor. This allows for maximal distri-
bution of energy and an increase in the size of the thermal
lesion. The alternating current generates ionic agitation,
creating a temperature as great as 100°C and resulting in
coagulative necrosis and tissue destruction in the vicinity of
the probe.
Since the widespread application of RFA for the ablation
of unresectable liver tumors, this technique has been con-
sidered as an alternate therapy for the destruction of other
solid tumors. Animal studies investigating the histologic
effects of RFA on pulmonary parenchyma revealed that
tumors can be ablated effectively, with minimal damage to
surrounding unaffected lung.6,7 The clinical experience of
RFA in the treatment of pulmonary malignancies is limited,
but unpublished large series from the People’s Republic of
China and pilot studies in the United States suggest that it
can be applied successfully with minimal complications.8-11
The objective of this study was to evaluate the effects of
RFA of lung tumors of patients ineligible for standard
surgical resection. Our main goal was to determine, in
preparation for a controlled prospective trial, the safety and
feasibility of this approach for treating malignant pulmo-
nary disease in patients who are not candidates for resection
by evaluating of early outcomes and radiographically deter-
mined response after RFA. Here we present our experience
with RFA for the treatment of malignant pulmonary disease
in patients not considered candidates for resection.
Methods
Patient Selection
We performed a retrospective review in the division of thoracic
surgery of all 18 patients with lung tumors treated with RFA at the
University Of Pittsburgh Medical Center from September 2000 to
March 2002 with approval from our institutional review board. We
selected patients who had failure of previous nonoperative thera-
pies or who, despite the presence of resectable disease, were
considered not to be candidates for complete resection because of
poor physiologic reserve or patient refusal. This group included
patients with both primary and secondary pulmonary tumors. All
patients had disease localized to the lungs, and treatment was
performed with the intent of cure or for local tumor control. In
light of the high risk associated with pulmonary resection in this
group of patients, it was considered that a minimally invasive
procedure could be a reasonable alternative because of the low
complication rates reported in patients treated with malignant liver
tumors, as low as 2.4% in the largest series to date.4
A total of 33 tumor nodules were treated in 18 patients, of
whom 3 patients underwent a second RFA procedure for residual
disease. Data resulting after retreatment with RFA in these 3
patients were excluded from data analysis, and the day of RFA
reapplication was considered the last point of follow-up. The
characteristics of treated patients and the main reasons for consid-
eration of RFA as an alternative to surgical resection are listed in
Table 1.
RFA Technique
The RFA procedure was performed by two thoracic surgeons in
the operating room with the patient under general anesthesia. The
lesion was approached by either minithoracotomy (5/18, 27%) or
the percutaneous route guided by computed tomography (CT,
13/18, 72%). In the CT-guided procedures we used the services of
a CT technician and used an operating room equipped with a CT
scanner. After confirming successful central placement of a finder
needle during CT imaging, the LeVeen needle electrode (Radio-
Therapeutics Corporation, Sunnyvale, Calif) size (2-4 cm) was
chosen according to the diameter of the target lesion. The needle
electrode has a diameter of 14 gauge with a 12- to 15-cm shaft
length and is introduced under CT guidance into the center of the
lesion, inside of which the multiple tines are deployed to maximize
the treatment area (Figure 1). Several applications in different
locations within the lesion may be required for larger masses, with
the therapy beginning at the most distal area and progressing
proximally. For RFA treatments by thoracotomy, the lesion is
TABLE 1. Characteristics of patients treated with RFA
Age (y, mean and range) 60 (27-95)
Sex (No.)
Male 12 (66%)
Female 6 (33%)
Previous therapy (No.)
Chemotherapy 15 (83.3%)
Radiotherapy 9 (50%)
Brachytherapy 1 (5.6%)
Photodynamic therapy 1 (5.6%)
Resection 9 (50%)
Main reason for no resection
Inadequate predicted postoperative pulmonary
reserve
12 (66.6%)
Refusal of surgery 3 (16.7%)
Severe chronic obstructive pulmonary disease
or cardiac risk
2 (11.1%)
Advance age (95 y) 1 (5.6%)
Tumor type
NSCLC 5 (27.8%)
Metastatic 13 (72.2%)
RFA approach
Minithoracotomy 5 (27.8%)
CT guided 13 (72.2%)
Hospital stay (d, mean and range) 3.4 (1-12)
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stabilized with the surgeon’s hand, and the needle electrode is
introduced guided by palpation and direct visualization.
Study End Points and Statistical Analysis
The objectives of this study were to determine early outcomes and
feasibility of RFA for malignant pulmonary tumors in patients not
considered candidates for surgery and to evaluate its effect on
radiographically determined tumor control. Specific end points
were description and frequency of complications, radiographic
evidence of tumor response after RFA treatment, and overall
survival.
Results from liver RFA suggest that larger tumors do not meet
with as good success rates as smaller lesions. We therefore sepa-
rately analyzed results for tumors smaller than 5 cm and those
larger than 5 cm, for the latter of which more than one deployment
of the RFA probe was always required. Patients underwent a chest
CT scan for preoperative evaluation and a repeated scan after the
RFA procedure before discharge from the hospital. Patient fol-
low-up was carried out at 1 month and then at 3-month intervals
with chest CT imaging. Additional imaging with positron-emis-
sion tomography (PET) was used selectively for suspected lesions
according to CT scan. Clinical response was evaluated by a com-
posite radiographic score comprising of tumor mass, tumor qual-
ity, and, when indicated, PET results. Changes in tumor mass were
measured with the Response Evaluation Criteria in Solid Tumors
(RECIST) protocol, which is based on objective measurements of
lesion size before and after treatment.12,13 Because RFA ablation
may cause accumulation of fluid and scar formation during the
Figure 1. RFA LeVeen needle electrode with deployed multi-tine array.
TABLE 2. RFA response criteria according to radiographic appearance of the treated lesion
Response CT mass size (RECIST) CT mass quality PET*
Complete (2 of
the criteria)
Lesion disappearance
(scar) or 25% of
original size
Cyst cavity formation,
low density
SUV 2.5
Partial (1 of the
criteria)
30% decrease in sum LD
of target lesions†
Mass central necrosis
or central cavity
with liquid density
Decreased SUV or
area of FDG
uptake
Stable lesion (1
of the criteria)
30% decrease in sum LD
of target lesions†
Mass solid
appearance, no
central necrosis or
cavity
Unchanged SUV or
area of FDG
uptake
Progression (2 of
the criteria)
Increase 20% in sum LD
of target lesions†
Solid mass, invasion
adjacent structures
Higher SUV or larger
area of FDG
uptake
Modified from the RECIST criteria.12,13 SUV, Standard uptake value; sum LD, sum of largest diameter of all target lesions; 18-FDG, 18-fluorodeoxyglucose.
*PET scan was used selectively in lesions with unclear response by CT imaging.
†Tumors treated with RFA.
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healing process, the effects on lesion size sometimes are minimal.
Instead, changes in the quality of the ablated tissue can be noted in
lesions successfully ablated with RFA. To account for this, we
modified the RECIST lesion response criteria to include a subjec-
tive evaluation of radiographic lesion characteristics on the basis
of central cavity formation or fluid accumulation (Table 2). In
addition, patients with lesions that were suspected of tumor per-
sistence after RFA or that showed poor response were evaluated
with 18-fluorodeoxyglucose PET scans, and the results were con-
sidered in the assessment of lesion response (Figure 2).
Descriptive statistics for the cohort were generated with SPSS
statistical software (SPSS Inc, Chicago, Ill). The nonparametric
Mann-Whitney test was used for analysis of ordinal variables, and
the 2 test was used for dichotomous variables.
Results
A total of 33 lung tumors in 18 patients were treated with
RFA (Table 3). There were 12 male and 6 female patients,
with a mean age of 60 years (range 27-95 years). RFA was
by either minithoracotomy (n  5) or percutaneous CT-
guided approach (n  13). The percutaneous approach
became our preferred option whenever feasible because of
the advantage of avoiding a thoracotomy. The 18 patients
treated had either primary NSCLC (n  5) or pulmonary
metastases from an extrathoracic malignancy (n  13).
Patients with pulmonary metastases had a median of 3
lesions (range 1-10) present at the time of RFA treatment,
and 5 of 13 (38%) had bilateral disease. The origins of the
primary tumors in patients with pulmonary metastases are
described in Table 3. Five patients had primary NSCLC, 2
of whom had recurrence of disease (M1) after previous
thoracotomy and resection (1 bronchoalveolar and 1 squa-
mous cell carcinoma). The stage distribution of patients
with NSCLC was as follows: stage Ia, 1; stage Ib, 2; and
stage IV, 2. The mean size of the largest treated lesions was
5.3 cm (range 2-16.1 cm). Median length of stay for patients
treated with RFA by the percutaneous approach was 2.5
days (range 1-5 days), versus 5 days (range 2-7 days) in the
group treated by minithoracotomy or with combination of
resection and RFA (P  .046 by Mann-Whitney test).
Chest tubes were placed in all open procedures and in 7
of 13 percutaneous treatments for procedure-related pneu-
Figure 2. A 56-year-old patient with stage 1b NSCLC and severe cardiac disease treated with RFA. A, Pre-RFA chest
CT scan demonstrating left upper lobe speculated 3.3-cm mass. B, Intraoperative image of RFA needle electrode
impaling the tumor via a percutaneous approach. C, CT scan 5 months after RFA. Note the central hypo-attenuation
and decreased density of the lesion. D, PET scan 5 months after RFA demonstrates left upper lobe lesion (arrow).
Note the central photopenia and peripheral rim of 18-fluorodeoxyglucose uptake with a standardized uptake value
of 1.5 (preoperative standardized uptake value 7.5).
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mothoraces. This complication was treated with placement
of pleural pigtail catheters during CT-guided RFA at the
time of the procedure to allow lung re-expansion and to
stabilize the tumor location. Median durations of chest tube
drainage were 3 days (range 1-6 days) for the open thora-
cotomy approach and 1.5 days (range 0-12 days) for the
CT-guided approach (P  .2 by Mann-Whitney test). Other
complications after lung RFA are described in Table 4.
Three patients underwent a second RFA procedure to treat
further metastatic disease, 1 of whom had new metastatic
lesions in the chest not present at the time of initial RFA. Of
these retreated patients, 1 died of massive hemoptysis 21
days after open RFA of a central nodule. This patient had
also received brachytherapy 4 days before this episode of
hemoptysis. After this complication, centrally located tu-
mors were excluded from treatment with RFA.
Response rates to RFA according to our response criteria
for all patients with lung tumors were as follows: complete
or partial radiographically evident response in 10 of 18
patients (55%), stable disease in 6 of 18 patients (33%), and
tumor progression in 3 of 18 patients (17%; Table 5). The
response rates seemed to be better for treated lesions smaller
than 5 cm (8/12, 66.6% response) than for those larger than
5 cm (2/6, 33.3% response) (P  .087 by 2 test). None of
the patients for whom a response was achieved had evi-
dence of tumor progression at the treated site; however, 5 of
9 patients with no response after RFA (55.5%) later showed
radiographic evidence suggestive of nodule recurrence or
progression (P  .0085 by 2 test). Of the 13 patients with
pulmonary metastasis, 7 (53.8%) had new lesions develop
in the chest and 4 (30.8%) had new extrathoracic metastases
develop.
At a median follow-up of 6 months (range 1-10 months),
4 of the 5 patients with NSCLC are alive; the other patient
died at the age of 95 years without evidence of disease
progression. Of the 4 patients with NSCLC who are alive at
last follow up, 3 patients have no evidence of disease. In the
group with pulmonary metastases, 7 of 13 (54%) are alive at
a median follow-up of 4 months (range 1-13 months).
Among the 6 patients with fewer than three metastatic
lesions and with a maximal tumor diameter of 5 cm, 5 are
alive at a median follow-up of 7 months (Table 6).
Discussion
The mainstay of treatment of early stage NSCLC and of
limited pulmonary metastases is standard surgical resection,
which provides better long-term survival than does nonop-
erative therapy.3,14 For patients who are medically unfit for
standard surgical therapy or could not tolerate complete
resection, the alternative treatment options are limited
mainly to chemotherapy and external beam radiation.
For patients with early stage NSCLC, available alterna-
tives to standard lobectomy or pneumonectomy are limited
resections or definitive high-dose radiotherapy. Limited re-
section, however, should continue to be viewed as a com-
promise operation for primary lung cancer because it carries
increased rates of locoregional recurrence.15 In addition,
this approach requires thoracoscopy or thoracotomy, which
may not be tolerated by patients with severe comorbidities
or may not be acceptable to patients who refuse surgical
intervention. As a second alternative, definitive radiation
therapy can be used in selected cases of medically inoper-
able early stage (I and II) NSCLC. In a meta-analysis
comprising 26 nonrandomized studies totaling more than
2000 patients, overall 5-year survival ranged from 0% to
TABLE 3. Tumor characteristics
No. %
NSCLC
Histologic type
Bronchoalveolar 1 20
Adenocarcinoma 1 20
Squamous cell carcinoma 1 20
Undetermined 2 40
Stage
Ia 1 20
Ib 2 40
IV 2 40
Size of treated lesion (cm)
2-3 3 60
1-4 2 40
Metastatic disease
Origin
Sarcoma 5 27.8
Colon 2 11
Melanoma 1 5.6
Head and neck 2 11
Genital 2 11
Renal 1 5.6
No. of metastases (median and range) 3 (1-10)
Size of largest lesion (cm)
2-4 5 38.5
4.1-6 3 23.1
6.1-10 3 23.1
10.1 2 15.4
Bilateral disease
Yes 5 38.5
No 8 61.5
TABLE 4. Complications after RFA
Complication No. %
Pleural effusion 9 50
Thoracocentesis 2 11
Pneumothorax (CT-guided group) 7 53.8
Delayed pneumothorax 1 5
Pneumonitis or pneumonia 4 22
Transient acute respiratory failure 1 5
Massive hemoptysis 1 5
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42%, with complete response rates between 33% and 61%.
However, reported local failure rates varied between 6%
and 70%.16 Similar results were reported in other retrospec-
tive studies, each comprising more than 140 patients with
stage I medically inoperable NSCLC, with overall 5-year
survivals of 13% to 22%, a cause-specific 5-year survival of
32%, and local failure rates of 42% to 44%.17,18
Patients with isolated pulmonary metastases from ex-
trathoracic malignancies who cannot undergo complete re-
section have poor survival. In a study of 5206 cases of lung
metastasectomy, the International Registry of Lung Metas-
tases reported an actuarial 5-year survival of 36%, which
compared favorably with a 5-year survival of 13% among
patients who underwent incomplete resection.3 Patients who
are not operative candidates for medical reasons have lim-
ited treatment options, because many secondary lung tu-
mors are not radiosensitive or comprise a large radiation
field. Furthermore, many of these patients have already had
failure of aggressive chemotherapy regimens by the time
they are seen for surgical consideration. There are no large
series of chemotherapy for isolated pulmonary metastases.
Response rates for metastatic colon carcinoma of 9% to
45% have been reported, but with a mean progression free
survival of 2 to 4 months.19,20
The major advantage of RFA therapy is that it allows
ablation of tumors without major damage to surrounding
normal parenchyma.6,7,21 In addition, the technique can be
performed percutaneously, thus avoiding a thoracotomy for
patients with severe comorbidities or those who refuse open
resection. These features make this technique a potential
tool for local control for certain patients who cannot un-
dergo standard surgical therapy. However, the efficacy of
RFA for the treatment of lung tumors is still unclear, and a
larger phase II study is necessary to determine its ablation
potential and its role in local tumor control relative to
standard radiation therapy.
RFA is now increasingly used for the treatment of he-
patic malignant tumors. Reported results vary according to
the series, and recurrence at treated sites is more likely after
ablation of larger lesions.5 Probably the best results are
those of 123 patients reported by Curley and associates.4
Initial successful ablation was seen in 100% of patients,
with local recurrence in 1.8% at a median follow-up of 15
months. Another series reported successful ablation of only
69% of 72 liver tumors.22 Our own data indicate that lung
RFA may not be as effective. This may be due in part to a
learning curve, however, particularly with percutaneous
techniques, and to patient selection, which did not exclude
patients with larger tumors. In addition, a more solid texture
of the tumor may allow more precise application of thermal
energy than could be achieved in the lung.
In this study we reviewed our initial experience with
RFA for the treatment of pulmonary malignancies in pa-
tients not considered surgical candidates. Because of the
limited clinical experience in the treatment of lung tumors
with RFA, we considered patients for this procedure if
TABLE 5. Determination of final radiographically evident response with each response criterion
Patient Tumor type
Nodules treated
with RFA (No.) RECIST
CT lesion
characteristics PET
Final
response
1 Metastatic, sarcoma 2 PD PR NA PR
2 Metastatic, sarcoma 1 PD PD NA PD
3 Metastatic, head and
neck
2 SD PR NA PR
4 Metastatic, colon 1 SD PR CR CR
5 Metastatic, sarcoma 1 SD SD NA SD
6 Metastatic, renal 2 SD PR NA PR
7 Metastatic, sarcoma 2 SD PD NA PD
8 Metastatic, cervix 1 PR PR NA PR
9 Bronchoalveolar 2 SD PR SD SD
10 NSCLC 1 SD SD NA SD
11 Metastatic, sarcoma 2 SD PD NA PD
12 NSCLC 1 SD PR CR PR
13 Metastatic, testicular 1 SD PR CR PR
14 Metastatic, head and
neck
3 PD PR SD SD
15 Metastatic,
melanoma
1 PD SD NA SD
16 Metastatic, head and
neck
2 PD PR PR PR
17 Metastatic, colon 2 SD SD NA SD
18 NSCLC 1 SD PR NA PR
PD, Progressive disease; PR, partial response; NA, not available; SD, stable disease; CR, complete response.
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resection was not possible because of patient comorbidity,
prohibitive pulmonary reserve, or patient refusal. Three
patients had failure of radiation or chemotherapy for exten-
sive disease localized to the chest for which RFA was
attempted as an adjunct to achieve local tumor control for
palliation. We have demonstrated that the procedure can be
performed either by thoracotomy or percutaneously with CT
guidance. Complication rates were acceptable in our initial
experience and consisted of pneumothoraces that resolved
in an average of 1 day in the patients treated percutaneously.
Pleural effusions were common but required drainage in
only 2 patients. We had 1 death in our experience, that of a
patient with massive hemoptysis 19 days after open RFA of
a central nodule. This patient had also received brachyther-
apy 4 days before his death. Although it is unclear which
therapy caused this complication, caution should be used
when applying RFA to central nodules near the hilum. Two
patients were readmitted with pneumonitis, and 1 patient
also had transient acute renal failure develop.
One of the difficulties with RFA therapy is evaluating the
response to treatment radiographically. In the experience
with liver tumors, radiographic assessment has been used
successfully to determine the effectiveness of RFA. Mainly
with the use of CT scans, changes in the quality of the
ablated lesion can be appreciated, with or without a decrease
in the volume or size of the lesion. Magnetic resonance
imaging has also been described for assessment of response
after RFA of liver lesions, because it can provide informa-
tion about the density and composition of the tumor, but we
have not used this modality for follow-up. Our approach to
assessing the tumor response was based on changes in the
size and quality of the ablated lesion on CT scans. The
addition of PET scans after RFA seems to define the effec-
tiveness of RFA treatment more clearly than do CT scans
alone, and PET scan may be useful to confirm the presence
of persistent disease in lesions that show growth or solid
appearance of the lesion on CT.
Of the 13 patients with pulmonary metastasis, 9 patients
(69%) had new metastases develop after RFA treatment,
and 5 of these 9 patients (56%) had new metastases develop
in the chest. In addition, in 3 of the 13 cases there were
radiographic changes suggestive of persistence or recur-
rence of the treated nodule. This could be explained in part
by the large size of the metastatic lesions treated, with a
mean size of 6.1 cm, a size for which RFA has shown
limited effectiveness in the treatment of liver tumors. Of the
13 patients with pulmonary metastases treated with RFA, 6
(46.1%) died during the follow-up period, again suggestive
of the extensive disease present in some of these patients.
Our initial experience suggests that RFA is technically
feasible with acceptable complication rates and could po-
tentially provide local control for selected patients with
malignant pulmonary tumors. Better selection criteria for
this therapy as part of a prospective clinical trial, together
with more standardized methods for radiographic follow-
up, are needed to demonstrate the effectiveness of RFA for
lung tumor ablation and its impact on patient survival.
Conclusions
RFA seems to be technically feasible for the treatment of
selected pulmonary tumors with acceptable complication
rates. Nine of 18 patients in whom a complete or partial
response was achieved were less likely to have a subsequent
recurrence in the RFA-treated lesions, but a significant
number of patients had new intrathoracic and extrathoracic
metastases develop after RFA. A trend toward a better
radiographically determined response was observed in pa-
tients with lesions smaller than 5 cm. Additional trials with
established patient selection criteria are needed to determine
the safety and efficacy of RFA and its impact on survival
relative to standard therapy. Thoracic surgeons must con-
tinue to evaluate minimally invasive techniques such as
RFA for local tumor control in patients thought not to be
surgical candidates.
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Discussion
Dr Richard Whyte (Palo Alto, Calif). I congratulate Herrera
and colleagues for continuing to push the envelope in both the
treatment of the thoracic malignant tumors and the role of the
surgeon in treating these ailments. This series presents the results
of RFA of 33 lung tumors in 18 patients. The sizes ranged from 1
to 16 cm, and the results showed that radiographic evidence of
improvement was common in the small lesions but less likely in
the large lesions. The procedure was reasonably safe, although
there was 1 death, and serious complications were uncommon. I
appreciate the reference to our article at The American Association
for Thoracic Surgery meeting, where we presented the results of
the combined experience of Stanford, M.D. Anderson, and Johns
Hopkins. We also found that small lesions were more reliably
ablated than larger ones. We also did all our procedures in an open
fashion and noticed a clear learning curve in positioning the
electrode.
I have three questions for Dr Herrera. First, do you think that
these arrays are better placed under CT guidance than through an
open thoracotomy? If so, should we as thoracic surgeons take steps
to learn CT-guided techniques?
Dr Herrera. Our experience suggests that it was more bene-
ficial for the patient to avoid a thoracotomy if the same result could
be achieved. In our experience the assistance of radiographic
imaging did help to place the electrode in the center of the lesion.
However, there are cases where the combination of resection with
ablation of a lesion in a separate lobe to avoid a second or third
resection would make a thoracotomy approach more beneficial. It
is too early to say. I think that it is going to come down in part to
surgeon’s preference.
Dr Whyte. It is my understanding that the University of Pitts-
burgh is unique in the sense that you have CT available to you in
the operating room, which most institutions do not have.
My second question relates to your criteria for evaluating the
response. Your criteria involve three components: CT-measured
size, CT-assessed quality, and PET scan results. I found it inter-
esting that size and quality results were only concordant in 5 of 18
patients. How did you account for these discrepancies and come up
with a “final response,” and how did this final response rate
translate into cure, which is the ultimate test of efficacy?
Dr Herrera. That is a good question. Obviously there are no
data available for how to evaluate these responses, so we tried to
generate criteria that were reproducible amongst our assessment.
In terms of size, you will notice that after therapy with RFA you
may see early on an increase in size with surrounding parenchymal
hemorrhage or pneumonitis. This tends to resolve, however, and
the size starts to decrease. Ours was a short follow-up so it is hard
to say what the outcome in terms of size is going to be, but we
suspect that responders are going to have a decrease or at least no
increase in lesion size. The discrepancies are true, but we put more
weight on the presence of cavity formation and PET also was
useful in complementing this assessment. I agree that the patient
population and the size were heterogeneous, and the assessment of
size in such a diverse group is a little bit more challenging.
Dr Whyte. Finally, what do you and your colleagues think
might be the ultimate role for RFA in the treatment of both primary
and metastatic lung cancers?
Dr Herrera. It is still too early to tell. I think that there may be
a role, and thoracic surgeons should consider this as a potential
tool for treatment of these challenging patients who cannot un-
dergo resection. These procedures are being done by radiologists
throughout the country, and with the advent of new CT screening
modalities I think the radiologists may have access to a lot of these
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lesions before thoracic surgeons do. So I think it is critical to select
patients who would not benefit from or cannot undergo a resection,
which I think is the ultimate therapy. I do not think that RFA will
substitute for current standard of surgical resection.
Dr John Mitchell (Denver, Colo). I have a question to follow
up on what Dr Whyte asked. It concerns the use of PET scanning
to evaluate response to therapy. I wonder whether the inflamma-
tory response induced by your therapy might confound the PET
results.
Dr Herrera. That is a good question. Unfortunately, only 6 of
the 18 patients had PET scans performed after RFA, and these
were done because of questionable responses in terms of CT
findings. I think that PET scan becomes a very useful modality in
combination with CT to provide a better assessment of response. It
is true that the inflammatory process that has been shown patho-
logically in animal studies can have uptake of 18-fluorodeoxyglu-
cose and yield a false result; however, we see that this rim
surrounding the tumor with central photopenia is characteristic of
a response, and the standard uptake values are much lower than in
the preoperative PET scan, which most patients underwent to
exclude extrathoracic disease.
Dr John R. Benfield (Los Angeles, Calif). In the practical
world I foresee this becoming a radiologic procedure, or at least
not a primary surgical procedure, in most centers. If that happens,
there will be a group of patients who will have complications from
the procedure—bronchopleural fistulas, empyemas, and so forth—
and will come to us as thoracic surgeons to manage. If that
happens, it is going to be hard for us to have an overview regarding
the efficacy and safety of the procedure.
I have two questions. First, at present is the procedure being
done in a small enough number of places that one could identify
those places and try to develop a prospective study?
Dr Herrera. Yes. As I understand, there are few published data
on this, but a few abstracts have been presented from two or three
centers. There is a radiologist at the University of Mississippi who
has performed more than 100 of these and claims a very good
success rate, better than 90%. These are unpublished data. There is
a Japanese group that has done more than 100 as well, and again
these are unpublished data, but they claim a good response as
assessed by PET scans. As we all know, Dr Whyte at Stanford and
M.D. Anderson and the University of Maryland have had some
experience with this. I think that the best way to assess it is to
establish critical or specific selection criteria and evaluate it that
way.
Dr Benfield. I think that is correct, but beyond that it would be
good, as was done in the early days of video-assisted thoracoscopic
surgery, if the centers doing this would pool their data and provide
a long-term follow-up. Only in this way would we know promptly
and accurately the true incidence of complications.
Dr Herrera. That is a good point. I think that in addition, we
are fortunate at the University of Pittsburgh to have an operating
room that belongs to the neurosurgeons, where they do their
stereotactic surgery. So in our case it is easier for our division of
thoracic surgery to perform these procedures, but I understand that
is not the case elsewhere.
Dr Matthew Blum (Chicago, Ill). I was wondering whether
the “rolloff” that you noticed has been correlated with complete
tumor ablation. Is the lung around the tumor relatively protected,
so that you can apply energy even beyond the rolloff to ensure that
you have tumor kill?
Dr Herrera. Right. Ideally you would want to ablate an area of
about 1 cm surrounding the lesion. Rolloff or the achievement of
impedance depends on the tumor size and the solid component of
the lesion. It does correlate. We did not look at that in particular,
but there have been animal studies that suggest that an inability to
achieve rolloff suggests an incomplete response or incomplete
ablation. It is something for which we would have to account for
in a prospective study.
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